Crown BioScience
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…
Latest
Crown BioScience
Growing the Future of Cancer Research: Inside the Promise of Organoids
In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…
Crown BioScience
Shaping the Future of Cancer Care Through Immuno-Oncology
In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed…
Crown BioScience
Evolving Biomarkers: Charting the Future of Precision Medicine
In a rapidly shifting landscape of personalized medicine, biomarkers have become central to shaping the way drug development and clinical trials unfold. From predicting therapeutic response to identifying optimal patient populations, the complexity and scope of biomarker use has increased alongside technological advances. A key success story like the BCR-ABL biomarker in chronic myeloid leukemia…
Crown BioScience
Exploring Artificial Intelligence in Drug Discovery
Artificial intelligence is rapidly reshaping the drug discovery process, moving from augmenting research to actively driving innovation. As biotech companies face soaring R&D costs and long development cycles, AI promises a breakthrough: slashing drug development time by nearly half while improving accuracy in identifying promising compounds. With global pharmaceutical R&D spending projected to exceed $230…
Crown BioScience
Pioneering Strategies to Unlocking the Potential of KRAS
Once labeled “undruggable,” KRAS has emerged as one of oncology’s most promising—yet complex—targets. With nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harboring KRAS mutations, the need for effective therapies is urgent. Recent FDA approvals of KRAS G12C inhibitors have signaled a new era, but the rise of resistance and diverse…
Latest
The Future of Employer Benefits: Balancing Rising Healthcare Costs with Creative, Employee-Centered Perks
The landscape of employee benefits has undergone a seismic shift in the last decade. From the rise of telemedicine to the introduction of lifestyle spending accounts and stipends for services like DoorDash and HelloFresh, employers are reimagining how they support workers in a post-pandemic, inflation-conscious world. With healthcare costs rising and talent competition intensifying,…
How Smart EHR Features Return Time to Patient Care: Insights from Healthcare Leaders
When Documentation Technology Finally Works for Clinicians At ChartLogic, we’ve spent years perfecting the features that matter most to healthcare providers. But rather than tell you what we think works, we wanted to hear directly from clinicians about the EHR capabilities that have genuinely improved their workflows. We asked healthcare professionals: Have you ever used…
From Green Initiatives to Guest Loyalty: Building the Future of Hospitality Through Tree Planting and Plastic Cleanup Programs
Sustainability is no longer optional in hospitality—it’s the expectation. A recent Booking.com report found that 84 percent of global travelers now prioritize making their trips more sustainable, raising the bar for hotels worldwide. Yet too many properties are still relying on the basics—like towel reuse cards or energy-saving reminders—that guests increasingly see as table stakes….
The Future of Directional Drilling: How Emerging Technologies Are Reshaping Performance Standards
Driving Innovation in Energy Exploration At Altitude Energy Partners, we’ve long understood that the future of energy development depends on continuous innovation in directional drilling technology. As formations become more complex and environmental standards more stringent, the industry is experiencing a technological revolution that promises to redefine what’s possible in drilling performance. We asked industry…
Latest CrownCast
Crown BioScience
Inside Oncology Drug Development: Overcoming Resistance with Science
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…
Growing the Future of Cancer Research: Inside the Promise of Organoids
In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…
Shaping the Future of Cancer Care Through Immuno-Oncology
In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed…
Evolving Biomarkers: Charting the Future of Precision Medicine
In a rapidly shifting landscape of personalized medicine, biomarkers have become central to shaping the way drug development and clinical trials unfold. From predicting therapeutic response to identifying optimal patient populations, the complexity and scope of biomarker use has increased alongside technological advances. A key success story like the BCR-ABL biomarker in chronic myeloid leukemia…
Crown BioScience
Exploring Artificial Intelligence in Drug Discovery
Artificial intelligence is rapidly reshaping the drug discovery process, moving from augmenting research to actively driving innovation. As biotech companies face soaring R&D costs and long development cycles, AI promises a breakthrough: slashing drug development time by nearly half while improving accuracy in identifying promising compounds. With global pharmaceutical R&D spending projected to exceed $230…
Pioneering Strategies to Unlocking the Potential of KRAS
Once labeled “undruggable,” KRAS has emerged as one of oncology’s most promising—yet complex—targets. With nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harboring KRAS mutations, the need for effective therapies is urgent. Recent FDA approvals of KRAS G12C inhibitors have signaled a new era, but the rise of resistance and diverse…
